首页 | 本学科首页   官方微博 | 高级检索  
     

莪棱胶囊防治卵巢子宫内膜异位囊肿术后复发及对在位、异位内膜组织MMP-9 mRNA和TIMP-1 mRNA作用的研究
引用本文:曹立幸,司徒仪,黄健玲,梁雪芳,向东方,冉青珍. 莪棱胶囊防治卵巢子宫内膜异位囊肿术后复发及对在位、异位内膜组织MMP-9 mRNA和TIMP-1 mRNA作用的研究[J]. 中国中西医结合杂志, 2008, 28(6): 541-544
作者姓名:曹立幸  司徒仪  黄健玲  梁雪芳  向东方  冉青珍
作者单位:广东省中医院,广州,510120
摘    要:目的 探讨术前应用中药莪棱胶囊防治卵巢子宫内膜异位囊肿(ovarian endometriosis, EMA)术后复发的作用和机制。

关 键 词:卵巢子宫内膜异位囊肿;莪棱胶囊;基质金属蛋白酶 9;基质金属蛋白酶组织抑制剂

Preventive and Therapeutic Effect of E-leng Capsule on Post-operation Recurrence of Ovarian Endometriotic Cysts and Its Influence on Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Eutopic and Ectopic Endometrium
CAO Li-xing,SITU Yi,HUANG Jian-ling. Preventive and Therapeutic Effect of E-leng Capsule on Post-operation Recurrence of Ovarian Endometriotic Cysts and Its Influence on Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Eutopic and Ectopic Endometrium[J]. Chinese journal of integrated traditional and Western medicine, 2008, 28(6): 541-544
Authors:CAO Li-xing  SITU Yi  HUANG Jian-ling
Affiliation:Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou. lixingcao@126.com
Abstract:OBJECTIVE: To investigate the effect and mechanism of E-leng Capsule (ELC) in preventing and treating post-operation recurrence of ovarian endometriotic cysts (OEC). METHODS: A total of 60 patients enrolled were the inpatients, who underwent cystectomy of OEC in the Gynecological Department of Guangdong Provincial Hospital of Traditional Chinese Medicine from 2002 to 2004. They were randomly assigned to two groups, the treatment group and the control group. Patients in the treatment group were administered with ELC before operation and after operation (starting from the 7th day post-operation), each for 3 months, while patients in the control group were untreated before operation and administered with Danazol from the 7th day post-operation for 3 months. Specimens of eutopic and ectopic endometrium in all patients of both groups were taken during the operation for detecting expressions of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA by polymerase chain reaction (PCR), and the incidence of post-operation recurrence was observed 12 months later. RESULTS: The 12-month follow-up showed that recurrence presented in 1 patient in the treatment group (3.3%), and 6 in the control group (20.0%), showing significant difference between them (P<0.05). The expressions of TIMP-1 mRNA in eutopic and ectopic endometrium were 0.85 +/- 0.36 and 0.76 +/- 0.57 in the treatment group, and 0.71 +/- 0.33 and 0.56 +/- 0.39 in the control group, while the expressions of MMP-9 mRNA were 0.36 +/- 0.40 and 0.35 +/- 0.35 vs 0.36 +/- 0.33 and 0.72 +/- 0.59, respectively. The expression of endometrial TIMP-1 mRNA, either eutopic or ectopic, was significantly higher, and the expression of ectopic endometrial MMP-9 mRNA was lower in the treatment group than that in the control group (P<0.01). CONCLUSION: ELC can reduce the invasive ability of endometrium tissue probably by regulating the balance of MMP/TIMP, namely, increase the expression of eutopic and ectopic endometrial TIMP-1 and decrease the expression of ectopic endometrial MMP-9, and thus to achieve its preventive and therapeutic effect on recurrence of OEC.
Keywords:ovarian endometriotic cyst  E-leng Capsule  matrix metalloproteinase-9  tissue inhibitor of matrix metalloproteinase-1
本文献已被 维普 万方数据 等数据库收录!
点击此处可从《中国中西医结合杂志》浏览原始摘要信息
点击此处可从《中国中西医结合杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号